2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
23
Fallopian Tube Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Breast Neoplasms
6
Multiple Myeloma
4
Stomach Neoplasms
2
Platinum-resistant Recurrent Ovarian Cancer
2
Ovarian Cancer Recurrent
2
Melanoma
2
Lymphoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Platinum-resistant Ovarian Cancer
1
Peritoneal Neoplasms
1
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Follicular
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumor
1
Interventions
atezolizumab
2
Gemcitabine
2
Cell Count
2
ziprasidone
1
valrubicin
1
tretazicar
1
pembrolizumab
1
liposomal doxorubicin
1
fludarabine phosphate
1
fludarabine
1
enadenotucirev
1
Zolpidem
1
Warfarin
1
Vecuronium Bromide
1
Vancomycin
1
Vaccines
1
Tumor Necrosis Factor-alpha
1
Tranexamic Acid
1
Tobramycin
1
Spironolactone
1
Sevelamer
1
Rocuronium
1
Radiotherapy
1
Piperacillin, Tazobactam Drug Combination
1
Pentobarbital
1
Oxycodone
1
Oncolytic Virotherapy
1
Nifedipine
1
Nafcillin
1
Molindone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenoviridae Infections
×
1-dodecylpyridoxal
×
Clear all
NCT05271318
2026-05-05
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2
Active not recruiting
29 enrolled